Join Fluence for an exclusive hour with Fluence Co-Founders, Ingmar Gorman PhD and Elizabeth Nielson PhD, who served as principal investigators and study therapists on the MAPS clinical trials looking at the efficacy of MDMA for PTSD, to unpack the FDA’s announcement on the status of MDMA which is expected by August 12.

All attendees will receive free access to Fluence on-demand Introduction to MDMA-assisted Therapy Research course!

The webinar will start with a 40 minute discussion as they debrief the details of the recent FDA decision on the approval of MDMA-assisted therapy for medical use in treating PTSD. This groundbreaking decision is set to revolutionize the treatment landscape for PTSD and the webinar will provide comprehensive insights into its implications for patients, healthcare providers, and the mental health industry.

Following the discussion, Fluence will open the floor to a Q&A session on Zoom, providing you with a unique opportunity to ask questions on the announcement. Whether you’re a mental health professional, a researcher, or someone with a personal or professional interest in MDMA and PTSD we plan to bring new insights and understanding to the news and what impact the decision will have. We hope you will join us for the live program but Fluence will record the discussion for those who can’t attend.  Register here to hear from top experts in the field and gain a deeper understanding of the FDA’s decision and its profound impact on the future of PTSD treatment.